Navigation Links
Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
Date:4/28/2009

s. AEs were reported in 70.3% subjects in the NT-201 group and 61.8% subjects in the placebo group. The most commonly reported AEs were eyelid ptosis (18.9 vs. 8.8%), dry eye (16.2 vs. 11.8%), and dry mouth (16.2 vs. 2.9%).

Clinical efficacy in focal dystonia and overall tolerability of NT-201 (botulinum neurotoxin free from complexing proteins) Presented by Susanne Grafe of Merz Pharmaceuticals GmbH, Frankfurt, Germany.

Methods

This study assessed the overall clinical efficacy and tolerability of NT-201 (botulinum neurotoxin free from complexing proteins). Efficacy analyses in focal dystonia were performed on pooled data from 2 pivotal clinical trials in blepharospasm and cervical dystonia (343 NT-201 patients; 340 BoNT patients). For the safety analyses, 6 clinical trials (blepharospasm, cervical dystonia and upper limb spasticity) were included (n=539 NT-201, n=442 BoNT and n=75 placebo subjects, respectively). Spontaneously reported adverse events were analyzed.

Results

In the randomized, active-controlled, double-blind studies in focal dystonia NT-201 and one other Botulinum toxin (BoNT) have been used with a dose ratio of 1:1. The results demonstrate equivalent efficacy between the two products. Onset, waning, and duration of effect were comparable. These findings have been confirmed by the Global Impression of Physician: 70.6% of BoNT patients and in 71.8% of the NT-201 patients were rated as "good" or "very good." A total of 26.7% of patients in the NT-201 group, 26.0% in the BoNT group and 22.7% in the placebo group reported an adverse event. There were no clinically relevant differences between the two treatment groups. All adverse reactions were either already known and/or were considered unlikely to be related to NT-201 by the physician. The analysis of the 67,000 patients treated post-launch dem
'/>"/>

SOURCE Merz Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
2. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
3. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
4. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
5. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
6. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
7. Trubion Pharmaceuticals, Inc. Announces Upcoming Presentation at the 2009 American Association of Cancer Research Annual Meeting
8. VentiRx Pharmaceuticals Initiates Phase I Clinical Trial of VTX-1463, a Novel TLR8 Agonist for the Treatment of Allergic Rhinitis
9. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
10. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
11. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... ST. LOUIS , July 11, 2014 ... medical device company, announced today the positive, ... of its innovative SPiNPerc™ procedure. The SPiNPerc ... use of a percutaneous approach to biopsy ... possible.  Hospitals, patients and physicians experience positive ...
(Date:7/10/2014)...  The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
Breaking Medicine Technology:Veran Medical Publishes Lung Cancer Patient Management Study 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2
... Inc. (Nasdaq: SVNT ) today announced that its ... by the U.S. Food and Drug Administration (FDA), a strategic ... in a sale of the Company at this time. The ... to the Company to maximize value. The ...
... HATBORO, Pa., Oct. 25 InfoLogix, Inc. ... provider of enterprise mobility solutions for the healthcare and ... at the South Florida Healthcare Trade Faire and Regional ... October 28, 2010 at the Signature Grand Hotel in ...
Cached Medicine Technology:Savient Pharmaceuticals Provides Update on Strategic Alternatives Process 2Savient Pharmaceuticals Provides Update on Strategic Alternatives Process 3InfoLogix to Present at South Florida Healthcare Trade Faire & Regional Conference 2
(Date:7/12/2014)... Burn injuries increase in the summer as people gather around ... those most vulnerable to these seasonal fire hazards: children. ... burned by putting their hands on the side of cooking ... at Loyola University Medical Center in Maywood, Ill., said in ... you play with fire, you get burned, is true -- ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As DePuy ... forward in U.S. courts, Bernstein Liebhard LLP notes the ... ion levels to the failure of metal-on-metal hip replacements. ... of The Journal of Bone & Joint Surgery, looked ... Articular Surface Replacement prostheses at least twelve months earlier. ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Doylestown Hospital ... a variety of men’s health questions. Paddock tackles ... to men, why women live longer than men, and ... Men's Health Made Simple featured on Doylestown Hospital’s ... a hernia at any age. If you notice pain, ...
(Date:7/12/2014)... Praeclarus Press is excited to offer ... resource for women in need of lactation support. Statistics ... from their children. Today’s mothers receive very clear messages ... often feel unsupported when it comes to balancing working ... insights, and written by Nancy Mohrbacher, an international breastfeeding ...
(Date:7/12/2014)... The largest pure occupational medicine company ... announce that it will be opening its fifth Georgia ... join four Atlanta-based Nova Medical Centers’ locations. The ... Bridge Road, and will be open from 8:30 a.m. ... Nova’s treatment philosophy of rapid return-to-work and decreased treatment ...
Breaking Medicine News(10 mins):Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Praeclarus Press Announces the Release of Working and Breastfeeding Made Simple by Nancy Mohrbacher, A Much Needed Resource For Today's Working Mothers 2Health News:Nova Medical Centers To Open New Facility in Augusta, Georgia 2
... ethnic disparities remain a challenge for patients in the ... (ACP) said in an updated paper released today. ... an update to a policy paper that was originally ... the gap between racial and ethnic minority patients and ...
... bioGUNE and led by Dr. Aitor Hierro, have opened ... of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), ... of the National Academy of Sciences of the ... possibility of research in humans to detect this pathology ...
... July 26, 2010 The Marilyn B. Gula ... breast cancer with a $50,000 donation to the Phoenix-based ... over two years of $300,000. In addition, the ... to Ohio,s University Hospitals (UH) Ireland Cancer Center, bringing ...
... cardiopulmonary bypass (CPB) during surgery for less complicated ... any impairments in neurocognitive abilities, such as intelligence, ... from The Children,s Hospital of Philadelphia, in a ... , reported on neuropsychological effects after surgery for ...
... Researchers at the University of California, San Diego School ... molecule common to chimpanzees, gorillas and other mammals but ... in some people, likely worsening conditions in which chronic ... acid sugar is an ingredient in some biotechnology drugs, ...
... By Suzanne Robitaille HealthDay Reporter , FRIDAY, July ... the 20th anniversary of the Americans with Disabilities Act on ... made meaningful progress in improving the quality of life for ... exist between the 54 million Americans with disabilities and those ...
Cached Medicine News:Health News:Disparities remain a challenge in health care says American College of Physicians 2Health News:New approach which can help to predict neurodegenerative diseases 2Health News:New approach which can help to predict neurodegenerative diseases 3Health News:The Marilyn B. Gula Mountains of Hope Foundation donates additional research funds to TGen 2Health News:Heart bypass for uncomplicated heart surgery does not reduce neurocognitive function in children 2Health News:Non-human sugar in biotech drugs causes inflammation 2Health News:Non-human sugar in biotech drugs causes inflammation 3Health News:Americans With Disabilities Act Reaches 20th Anniversary 2Health News:Americans With Disabilities Act Reaches 20th Anniversary 3Health News:Americans With Disabilities Act Reaches 20th Anniversary 4
... high-power, apochromatically corrected objectives ... the most exacting demands ... are suitable for visual ... 25 mm and feature ...
... transmission rate in the ultraviolet down to ... fluor-3; these objectives have,improved signal to noise ... Numerical Apertures for significantly sharper and brighter ... and a 2mm working distance to allow ...
... Featuring longer working distances with high ... to correct all optical aberrations throughout the ... centre to edges across the entire 25mm ... image flatness and colour reproduction, plus resolving ...
... an extra-high transmission rate, especially in ... to the CFI plan Achromat series, ... observation and photomicrography. Because of ... as multipurpose objectives for brightfield, fluorescence, ...
Medicine Products: